Literature DB >> 10206826

Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

E A Jones1, A S Basile.   

Abstract

The ammonia and GABAergic neurotransmission hypotheses of the pathogenesis of hepatic encephalopathy (HE) have appeared to be unrelated and perhaps mutually exclusive. Observations in animal models of fulminant hepatic failure, that are consistent with increased GABAergic inhibitory neurotransmission contributing to the manifestations of HE, include: (i) abnormal visual evoked potential waveforms that resemble those induced by GABA(A)/benzodiazepine (BZ) receptor complex agonists; (ii) GABA(A)/BZ receptor complex antagonist-induced ameliorations of encephalopathy; (iii) increased resistance to drugs which decrease GABAergic tone; and (iv) hypersensitivity of CNS neurons to depression by GABA(A)/BZ receptor complex agonists. Mechanisms of increased GABAergic tone in HE may include the following: (i) increased brain concentrations of natural BZs; and (ii) increased GABA concentrations in synaptic clefts, possibly due to increased blood-brain-barrier permeability to GABA and a decrease in GABA(B) receptor density. Both neuroelectrophysiological and behavioral data indicate that ammonia concentrations in the range 0.75-2 mM induce increased excitatory neurotransmission. In contrast, recently, ammonia concentrations in the range 0.15-0.75 mM, i.e. concentrations that commonly occur in plasma in precoma HE, have been shown: (i) to increase GABA-induced chloride current in cultured neurons; and (ii) to enhance synergistically the binding of GABA(A)/BZ receptor agonists. In addition, increased ammonia concentrations enhance synthesis of neurosteroids in astrocytes, and some neurosteroids potently augment GABAergic neurotransmission. Thus, the modestly elevated concentrations of ammonia, that commonly occur in liver failure, may contribute to the manifestations of HE by enhancing GABAergic inhibitory neurotransmission. This concept appears to unify the ammonia and GABAergic neurotransmission hypotheses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10206826     DOI: 10.1023/a:1020693026810

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  42 in total

1.  Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

Authors:  A S Basile; R D Hughes; P M Harrison; Y Murata; L Pannell; E A Jones; R Williams; P Skolnick
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

Review 2.  Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy.

Authors:  A S Basile; E A Jones
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

Review 3.  Newer approaches to therapy of hepatic encephalopathy.

Authors:  P Ferenci; A Herneth; P Steindl
Journal:  Semin Liver Dis       Date:  1996-08       Impact factor: 6.115

4.  Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy.

Authors:  A S Basile; S H Gammal; K D Mullen; E A Jones; P Skolnick
Journal:  J Neurosci       Date:  1988-07       Impact factor: 6.167

Review 5.  Neurosteroids and GABAA receptor function.

Authors:  J J Lambert; D Belelli; C Hill-Venning; J A Peters
Journal:  Trends Pharmacol Sci       Date:  1995-09       Impact factor: 14.819

6.  Plasma GABA, GABA-like activity and the brain GABA-benzodiazepine receptor complex in rats with chronic hepatic encephalopathy.

Authors:  J E Maddison; P R Dodd; M Morrison; G A Johnston; G C Farrell
Journal:  Hepatology       Date:  1987 Jul-Aug       Impact factor: 17.425

7.  Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

Authors:  M Olasmaa; J D Rothstein; A Guidotti; R J Weber; S M Paul; S Spector; M L Zeneroli; M Baraldi; E Costa
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

8.  The contribution of endogenous benzodiazepine receptor ligands to the pathogenesis of hepatic encephalopathy.

Authors:  A S Basile
Journal:  Synapse       Date:  1991-02       Impact factor: 2.562

9.  Acute liver failure and hyperammonemia increase peripheral-type benzodiazepine receptor binding and pregnenolone synthesis in mouse brain.

Authors:  Y Itzhak; A Roig-Cantisano; R S Dombro; M D Norenberg
Journal:  Brain Res       Date:  1995-12-24       Impact factor: 3.252

10.  In vivo studies of GABAergic effects in experimental hepatic encephalopathy.

Authors:  D Rzepczynski; L Zieve; S Lindblad; D LaFontaine
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

View more
  13 in total

1.  Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.

Authors:  E A Jones; V I Giger-Mateeva; D Reits; F C Riemslag; B Liberov; H Spekrijse
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 2.  Functional imaging of the brain in patients with liver cirrhosis.

Authors:  Karin Weissenborn; Martin Bokemeyer; Björn Ahl; Daniela Fischer-Wasels; Kathrin Giewekemeyer; Jörg van den Hoff; Herbert Köstler; Georg Berding
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 3.  Effects of hyperammonemia on brain energy metabolism: controversial findings in vivo and in vitro.

Authors:  Arne Schousboe; Helle S Waagepetersen; Renata Leke; Lasse K Bak
Journal:  Metab Brain Dis       Date:  2014-03-01       Impact factor: 3.584

4.  Hyperammonemia and chronic hepatic encephalopathy: an in vivo PMRS study of the rat brain.

Authors:  D Astore; C A Boicelli
Journal:  MAGMA       Date:  2000-07       Impact factor: 2.310

5.  Human (13)N-ammonia PET studies: the importance of measuring (13)N-ammonia metabolites in blood.

Authors:  Susanne Keiding; Michael Sørensen; Ole Lajord Munk; Dirk Bender
Journal:  Metab Brain Dis       Date:  2010-03-09       Impact factor: 3.584

6.  Enhanced sedative efficacy and delayed recovery in propofol anesthesia in a rat model of hepatic cirrhosis.

Authors:  Xuexin Chen; Rui Yan; Zhixia Bai; Hanxiang Ma
Journal:  Int J Clin Exp Med       Date:  2015-04-15

7.  Expression of Glutamate Decarboxylase (GAD) mRNA in the brain of bile duct ligated rats serving as a model of hepatic encephalopathy.

Authors:  Renata Leke; Themis R Silveira; Thayssa D C Escobar; Arne Schousboe
Journal:  Neurochem Res       Date:  2013-08-01       Impact factor: 3.996

Review 8.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 9.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Impairment of short term memory in rats with hepatic encephalopathy due to bile duct ligation.

Authors:  Renata Leke; Diogo L Oliveira; Luiz F Forgiarini; Thayssa D C Escobar; Thais O Hammes; Fabíola S Meyer; Susanne Keiding; Themis R Silveira; Arne Schousboe
Journal:  Metab Brain Dis       Date:  2012-11-01       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.